Medtronic to begin drug-filled stent clinical trial in Australia and Brazil
Medtronic is planning to start the drug-filled stent (DFS) trial at several sites in Australia and Brazil. The strategic decision is based on the results of the stent’s preclinical studies, in which DFS exhibited a controlled and efficacious drug release into the arterial wall without a polymer carrier, along with reduced stenosis and inflammation. 100 patients will be enrolled for the trial to evaluate late lumen loss. The device has a tri-layer wire design, which helps to remove the innermost layer and the drug is released from the core upon the stent surface through albuminal side holes, leading to the polymer-free drug release during the required interval of time. The new DFS stands on the platform of Resolute Integrity DES with Continuous Sinusoid Technology and the Resolute Onyx DES with CoreWire Technology.